ARTICLE | Clinical News
Cotsiranib: Ph IIa started
February 16, 2017 8:14 PM UTC
Sirnaomics began a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate 20, 30 and 40 μg/cm2/day intradermal cotsiranib twice weekly for 4 weeks in about 24 patients. Patients will recei...
BCIQ Company Profiles
BCIQ Target Profiles